We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GENRUI BIOTECH INC.

SEBIA

Sebia provides clinical protein electrophoresis equipment and reagents for in-vitro diagnostic testing, including sys... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

Paraproteins Identification Methods Compared for Monoclonal Gammopathies

By LabMedica International staff writers
Posted on 18 Mar 2021
Print article
Image: The HYDRASYS 2 Electrophoresis Automated System (Photo courtesy of Sebia).
Image: The HYDRASYS 2 Electrophoresis Automated System (Photo courtesy of Sebia).
Monoclonal gammopathy, also known as paraproteinemia, is the presence of excessive amounts of myeloma protein or monoclonal gamma globulin in the blood. It is usually due to an underlying immunoproliferative disorder or hematologic neoplasms, especially multiple myeloma.

In monoclonal gammopathies, the full laboratory workup for initial diagnosis and disease relapse includes a complete blood count and differential, a peripheral blood smear, a chemistry screen including calcium and creatinine, serum protein electrophoresis, serum immunofixation (IFE), immunoturbidimetric or immunonephelometric quantification of serum Ig, routine urinalysis, 24-hour urine collection for electrophoresis and immunofixation, serum β2-microglobulin, lactate dehydrogenase, and measurement of serum free light chains.

Medical Laboratory Scientists at the MDI Limbach Berlin GmbH (Berlin, Germany) evaluated methodic differences between serum immunofixation and serum immunosubtraction as well as in the quantitation of serum immunoglobulins on different clinical chemical platforms. The scientists used 322 unique routine patient samples and used for comparison between serum immunofixation (IFE) on HYDRASIS 2 (Sebia, Lisses, France) and serum immunosubtraction (ISE) on Sebia's CAPILLARYS 2 as well as between quantitation results of immunoglobulin A, G, and M on the ARCHITECT c16000PLUS (Abbott Core Laboratory, Abbott Park, IL, USA) and the Cobas c 502 module (Roche Diagnostics, Rotkreuz, Switzerland). The median age of patients was 75 years.

The scientists reported that IFE detected and identified a total of 69 paraproteinemias, while ISE only detected monoclonal proteins in 51 samples, a difference of 26%. ISE failed to detect 6/7 samples with biclonal paraproteinemias as well as 8/11 monoclonal paraproteins involving IgA and 4/10 monoclonal paraproteins involving IgM identified by IFE. For monoclonal paraproteins involving IgG, the total number of detections was 39 in IFE and 38 in ISE. Samples with paraproteinemia were nearly evenly split between sexes. Paraprotein identification differed remarkably between immunofixation and immunosubtraction. Quantitation of serum immunoglobulins showed higher values on Abbott's ARCHITECT c16000PLUS when compared with Roche's Cobas c 502 module.

The authors concluded that identification of paraproteins via serum immunosubtraction is inferior to serum immunofixation, which can have implications on the diagnosis and monitoring of patients with monoclonal gammopathy. If immunoturbidimetric quantitation of immunoglobulins is used for follow-up, the same clinical-chemical platform should be used consistently. The study was published on February 26, 2021 in the journal Archives of Pathology and Laboratory Medicine.

Related Links:
MDI Limbach Berlin GmbH
Sebia
Abbott Core Laboratory
Roche Diagnostics


Gold Supplier
Clinical Chemistry Series
Clinical Chemistry Series
New
Gold Supplier
Tumor Marker Control
Tumor Marker Control
Laboratory Automation Solution
SATLAS-TCA
COVID-19 Anitibody Test
TGS COVID-19 IgG

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more

Industry

view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.